Abstract CT112: An off-the-shelf multivalent vaccine containing cancer’s dark matter, DPV-001, combined with PD-1 +/- GITR in head & neck cancer: safety, efficacy, and immunodynamics from the phase 1 GITRVax trialRom S. Leidner, Bernard A. Fox, Tijana Jovanović‐Talisman et al.|Cancer Research|2024Cited by 3
1481 Off-the-shelf dark matter immunotherapy in head & neck cancer: mechanistic insights and clinical efficacyRom S. Leidner, Bernard A. Fox, Christopher Paustian et al.|Unknown|2024Cited by 1
Phenotypic and clonal evolution of CD4 T cells in HNSCC during immunotherapy: a case report 3277Christopher Paustian, B. Fox, Tarsem Moudgil et al.|The Journal of Immunology|2025Cited by 0
CMS subtypes correlate with complete response in trial of neoadjuvant Galunisertib plus chemoradiation in rectal cancerVenkatesh Rajamanickam, Kristina H. Young, Noah D. Simons et al.|Translational Oncology|2026Cited by 0
Abstract LB425: Search for targets of anti-cancer immunity in patients receiving an off-the-shelf cancer’s dark matter vaccine, DPV-001, combined with anti-PD-1 +/- anti-GITR in head and neck squamous cell cancer (HNSCC)Traci Hilton, Bernard A. Fox, Ryan Meng et al.|Cancer Research|2026Cited by 0